Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials

L Collette, T Burzykowski, Fritz Schröder

Research output: Contribution to journalArticleAcademicpeer-review

67 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1344-1350
Number of pages7
JournalEuropean Journal of Cancer
Volume42
Issue number10
DOIs
Publication statusPublished - 2006

Cite this